← Back to Search

Cancer Vaccine

Vaccine Therapy for Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by Epimmune

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 and over

Renal criteria: Creatinine ≤ 2 times ULN

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying a vaccine made from peptides to see how well it works in treating patients with non-small cell lung cancer.

Who is the study for?

This trial is for adults with stage IIIB, IV, or recurrent non-small cell lung cancer. Participants must have a certain level of blood and organ function, no brain metastases symptoms, not be pregnant or nursing, use contraception if fertile, and have no other cancers in the past 5 years. They should also not have autoimmune diseases or HIV.Check my eligibility

What is being tested?

The study is testing how well a vaccine therapy works against non-small cell lung cancer. The vaccine aims to stimulate the body's immune system to attack and kill cancer cells. This phase II trial will assess the effectiveness of this treatment approach.See study design

What are the potential side effects?

While specific side effects are not listed here, vaccines can typically cause reactions at the injection site like redness and pain, flu-like symptoms such as fever and chills, fatigue, headache and muscle pains.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My kidney function, measured by creatinine, is within normal limits.

Select...

My disease is HLA-A2 positive.

Select...

My cancer can be measured by tests.

Select...

I am fully active or can carry out light work.

Select...

My lung cancer is at an advanced stage (IIIB, IV) or has come back.

Select...

My tumor is small, less than 125 cubic centimeters.

Select...

I do not have brain metastases symptoms.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparison of overall survival with historical controls

Safety

Secondary outcome measures

Frequency, magnitude, and breadth of cytotoxic and helper T-cell response to vaccine epitopes

Progression-free survival

0 / 8Eligibility criteria met

Find a Location

Who is running the clinical trial?

EpimmuneLead Sponsor

3 Previous Clinical Trials

68 Total Patients Enrolled

Scott PlasmanStudy ChairEpimmune

Media Library

Vaccine Therapy (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT00104780 — Phase 2

Lung Cancer Clinical Trial 2023: Vaccine Therapy Highlights & Side Effects. Trial Name: NCT00104780 — Phase 2

Vaccine Therapy (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00104780 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any individuals currently needed to participate in this research?

"This particular clinical trial, which was originally posted on December 1st, 2004 and last updated on November 5th, 2013, is not currently recruiting patients. Despite this fact, there are over two-thousand other trials that are actively looking for participants right now."

Answered by AI

Is this research being conducted in a large number of hospitals statewide?

"New york Oncology Hematology, P. C., Albany Regional Cancer Care, Cancer Centers of Florida - Ocoee, Sarah Cannon Cancer Center at Centennial Medical Center, and 9 other locations are the main sites for this trial."

Answered by AI

Has this treatment received regulatory approval from the FDA?

"As this is a Phase 2 trial, there is some data indicating that the treatment might be safe but no data yet on whether or not it effective. Our team rates the safety at a 2."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

2004. "Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00104780.

All > Lung > Sclc